Alpha memo: urolithin mitochondrial signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Substantively compare the two receipts on shared dimensions (endpoint type, model system, direction of effect, magnitude) and derive a grounded claim rather than asserting non-transfer by default.
2. If the intended alpha is that in vitro AD-cell mitochondrial findings do not automatically generalize to human cardiovascular endpoints, state that explicitly and justify it with the specific endpoint/metric differences between the two receipts.
3. Provide a quantitative or directional comparison (e.g., what Receipt 1 measured vs what Receipt 2 measured, and where effects were observed or absent in each).
4. Remove or revise the framing that the two receipts 'do not carry one stable direction' unless the receipts actually show divergent directions on a comparable endpoint.

Major issues

• The memo's central claim ('does not carry one stable direction across the two receipts') is contradicted by the actual source material: Receipt 1 (cellular AD model) reports mitochondrial effects of UA, and Receipt 2 (preclinical cardiac + human cardiovascular biomarkers) also reports positive mitochondrial/functional effects. Both receipts point in a broadly concordant direction on mitochondrial parameters; the memo manufactures a 'split' that the bundle does not support.
• The research question ('How far does the Receipt 1 signal transfer across the setting tested by Receipt 2?') is not directly answered. No quantitative or qualitative comparison of effect direction, magnitude, or endpoint overlap is provided — the memo asserts non-transferability without evidence-grounded justification.
• Receipt 1 excerpt cited in the memo ('Treatment of SH-SY5Y-APP695 cells suggests changes to autophagy corresponding with qRT-PCR results') and Receipt 2 excerpt ('reduced both systolic and diastolic cardiac dysfunction') both describe positive UA mitochondrial effects. The memo's framing of a bounded contrast or non-transfer is not derivable from these excerpts.
• The memo implicitly treats 'no universal claim possible from two heterogeneous studies' as a research signal, which is a methodological truism, not a substantive alpha. This is structurally a non-finding dressed as a bounded contrast.
• Title/source alignment: the title promises a 'urolithin mitochondrial signal' but the memo delivers a meta-commentary on cross-study generalizability rather than any specific mitochondrial signal grounded in the two receipts.

Minor issues

• The 'bounded contrast' axes line ('function' vs 'adults, human, cardiac, function') is informal and does not clearly specify which endpoint or population differs between the two receipts in a way that explains the asserted non-transfer.
• Excerpts in the 'Synthesis' section are pasted verbatim but the connecting argument is absent.

Reviewer note

The submission claims to deliver a bounded, source-grounded alpha on urolithin/mitochondrial effects by comparing a 2021 cellular Alzheimer model study with a 2025 preclinical/human cardiovascular study. However, both receipts describe broadly positive mitochondrial effects of urolithin A in their respective settings; the memo's central assertion that the signal 'does not carry one stable direction' is not supported by the cited excerpts and reads as a manufactured non-finding. The research question is stated but not answered with evidence-grounded comparison. The synthesis does not integrate the two receipts on any shared axis. The memo would require a scope reset and substantive reworking of both the central claim and the comparison logic before it could be accepted.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis